Nivolumab, used in the first-line treatment of patients with advanced hepatocellular carcinoma (HCC), has demonstrated clinically meaningful improvements in overall survival (OS) and response rates vs sorafenib in the phase III CheckMate 459 study, although the improvement in OS did not reach statistical significance.
Intelligent Liver Function Testing (iLFT), an automated investigation algorithm for liver function tests (LFTs), is highly cost-effective, leading to higher rates of liver diagnoses and improvements in quality of care, according to a new study.
Pembrolizumab improved progression-free survival (PFS) and overall survival (OS) over best supportive care in patients with advanced hepatocellular carcinoma (HCC), according to the phase III KEYNOTE-240* trial, supporting its role as a treatment option for HCC in the second-line setting.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 20190910083343
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
DOACs* were better than warfarin in terms of efficacy and safety for stroke prevention in an Asian population with atrial fibrillation (AF) and liver disease, including patients with significant active liver disease who were usually excluded from pivotal clinical trials, suggests a study based on the Korean national database.
New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) suffer from higher surgical morbidity and posthepatectomy liver failure, according to a new Singapore study.
A Singapore study has shown the association of nosocomial spontaneous bacterial peritonitis (N-SBP) with recent antibiotic use, longer hospitalization, more resistant organism and poorer survival among patients with SBP. Moreover, N-SBP and Model for End-stage Liver Disease (MELD) score are predictors of higher mortality in SBP.